Novo Nordisk’s Wegovy and copyright, each powered by semaglutide, have revolutionized weight problems cure by unprecedented weight loss effects.In October 2024, Novo Nordisk published a research on scientific journal Mother nature about a novel glucose-sensitive insulin NNC2215 that may reduce the potential risk of hypoglycemia in animal products